Deutsche Bank retained AstraZeneca PLC (LON:AZN) to Buy in a report released today.
- Updated: November 29, 2016
Deutsche Bank has retained AstraZeneca PLC (LON:AZN) to Buy in a report released on Wednesday November 30, 2016.
Previously on 11/28/2016, JP Morgan Cazenove reported on AstraZeneca PLC (LON:AZN) reduced the target price from 4,900.00GBX to 4,600.00GBX. At the time, this indicated a possible upside of 0.08%.
Yesterday AstraZeneca PLC (LON:AZN) traded -0.11% lower at 4,244.75GBX. The company’s 50-day moving average is 4,592.74GBX and its 200-day moving average is 4,592.37GBX. The last closing price is down -7.64% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 268,678 shares of the stock traded hands, down from an average trading volume of 2,615,250
See Chart Below
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a P/E ratio of 21.76 The company’s market capitalization is currently 0 GBX.
In addition to Deutsche Bank reporting its stock price target, a total of 29 brokerages have issued a ratings update on the company. The average stock price target is 61.96GBX with 4 brokerages rating the stock a strong buy, 14 brokerages rating the stock a buy, 13 brokerages rating the stock a hold, 2 brokerages rating the stock a underperform, and finally 1 brokerage rating the stock a sell.
Brief Synopsis On AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.